All In Biotech

NDA 019828 · Fougera

Oxistat

Oxiconazole Nitrate · Topical

Novel

Last checked: Nov 20, 2026Latest source record: Jan 23, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Dec 30, 1988

Approved uses

4

Original approval plus efficacy supplements

Registered trials

4

0 Phase 3, 0 recruiting

FAERS reports

171

75 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 28, 2026.

INDICATIONS AND USAGE Oxiconazole nitrate cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. Oxiconazole nitrate cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Oxiconazole nitrate cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which oxiconazole nitrate cream has been shown to be effective rarely occur in children below the age of 12.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 18, 1997 Supplement 7 · Efficacy
  • Aug 18, 1997 Supplement 3 · Efficacy
  • Sep 30, 1992 Supplement 5 · Efficacy
  • Dec 30, 1988 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • OXISTAT · OXICONAZOLE NITRATE EQ 1% BASE · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxiconazole Nitrate" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective19
  • rash16
  • pruritus13
  • arthralgia10
  • headache10
  • chronic kidney disease8
  • erythema8
  • nausea8
  • pain7
  • rash papular7
  • renal failure7
  • blister6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20053
20064
20081
20091
20102
20116
201210
20138
20147
201520
201617
201711
201815
201916
202015
20217
202216
20233
20241
20253
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Oxistat (Oxiconazole Nitrate)

2024 spending

$246K

Beneficiaries

161

295 claims

Per beneficiary

$1,531

$14.39 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$251,070
2024$246,452

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Fougera

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.